Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00600951 · ClinicalTrials.gov registry record
Evaluation of the Risk of NSF Following MultiHance Injection in Patients With Chronic Kidney Disease
A clinical trial of Renal Insufficiency, sponsored by Bracco Diagnostics.
- Completed
- Registry status
- 366
- Enrollment target
- 1
- Study location
NCT00600951 is a study of Renal Insufficiency that has completed, run by Bracco Diagnostics. The registered enrollment target is 366 participants, above the 85-participant average among 22 other Renal Insufficiency trials with a reported enrollment target (331% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00600951, a study of Renal Insufficiency, has completed, sponsored by Bracco Diagnostics.
- COMPLETED
- Registry status
- 366 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this long-term study is to prospectively compare the incidence of NSF in two cohorts (Cohort 1 - patients with moderate chronic kidney disease eGFR 30 to 59 and Cohort 2 - patients with severe chronic kidney disease or kidney failure eGFR \<30).
Conditions Studied
Study Locations (1)
New Jersey
- Bracco Diagnostics Inc. - Princeton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 366 participants |
| Start Date | 2008-01 |
| Est. Completion | 2013-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00600951
The ClinicalTrials.gov registry entry for NCT00600951 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 366 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 85-participant average among 22 other Renal Insufficiency trials with a reported enrollment target (331% higher). The listed sponsor is Bracco Diagnostics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Insufficiency appearing as the primary indexed condition, and to 0 interventions.
NCT00600951 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT00600951 about?
NCT00600951 is a clinical study titled "Evaluation of the Risk of NSF Following MultiHance Injection in Patients With Chronic Kidney Disease". The objective of this long-term study is to prospectively compare the incidence of NSF in two cohorts (Cohort 1 - patients with moderate chronic kidney disease eGFR 30 to 59 and Cohort 2 - patients with severe chronic kidney disease or kidney failure eGFR \<30).
What is the current status of trial NCT00600951?
This trial is currently completed. The enrollment target is 366 participants. The study started on 2008-01. Estimated completion is 2013-08.
What conditions does trial NCT00600951 study?
This clinical trial studies the following conditions: Renal Insufficiency.
Who is sponsoring clinical trial NCT00600951?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00600951 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Insufficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
RECRUITING · NA
-
A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function
RECRUITING · Phase 1
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment
COMPLETED · Phase 1
-
"Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction"
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.